Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats
Open Access
- 11 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 91 (4), 632-639
- https://doi.org/10.1093/cvr/cvr133
Abstract
Vitamin D deficiency is associated with cardiac hypertrophy and heart failure, and vitamin D therapy prevents the progression of cardiac hypertrophy in animal models. Here, we examine whether vitamin D therapy prevents progression of pre-existing cardiac hypertrophy and development of heart failure. When male Dahl salt-sensitive rats were fed a high salt (HS) diet, all rats developed cardiac hypertrophy after 5 weeks. Thereafter, rats were treated with vehicle (V), paricalcitol (PC, an active vitamin D analogue, at 200 ng, IP 3x/week), enalapril (EP, 90 μg/day), and PC + EP. All groups were continued on the HS diet and evaluated after 4 weeks of therapy. The PC and PC + EP groups, but not the V and EP only groups, showed significant prevention of progression of pre-existing cardiac hypertrophy. The signs of decompensated heart failure were evident in the vehicle-treated group; these heart failure parameters significantly improved with PC, EP or PC + EP therapy. The expression of PKCα, which is regulated by Ca2+and known to stimulate cardiac hypertrophy, was significantly increased in the vehicle group, and PC, EP or PC + EP effectively decreased PKCα activation. We also observed normalization of genetic alterations during progression to heart failure with PC treatment. PC treatment resulted in both the prevention of progression of pre-existing cardiac hypertrophy and the development of heart failure, compared with improvement in progression to heart failure by EP alone. These beneficial findings in heart were associated with inhibition of PKCα activation and reversal of gene alterations.Keywords
This publication has 39 references indexed in Scilit:
- Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt-sensitive ratsCardiovascular Research, 2009
- Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cβ2 in the regulation of physiologic developmental hypertrophy and heart functionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Expression of the Vitamin D Receptor Is Increased in the Hypertrophic HeartHypertension, 2008
- Vitamin D Deficiency and Risk of Cardiovascular DiseaseCirculation, 2008
- Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animalsProceedings of the National Academy of Sciences of the United States of America, 2007
- Vitamin D DeficiencyThe New England Journal of Medicine, 2007
- Response of caspase-independent apoptotic factors to high salt diet-induced heart failureJournal of Molecular and Cellular Cardiology, 2007
- 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyteThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Characterization of heart size and blood pressure in the vitamin D receptor knockout mouseThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin systemJCI Insight, 2002